Clinical Trial

A Study of STM-416 Administered to Patients Undergoing TURBT for Recurrent Bladder Cancer

Name: A Study of STM-416 Administered to Patients Undergoing TURBT for Recurrent Bladder Cancer — clinical trial record (NCT05710848)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 1/2

View on ClinicalTrials.gov →

Summary

This is a first-in-human (FIH), Phase 1/2a, multi center, open-label, single treatment, dose escalation and expansion study designed to determine the safety and tolerability of STM-416 in patients with bladder cancer.

Protocol Amendment History 1 change

notable Trial sites expanded: 10 -> 20 locations 2026-05-28

Trial Details

NCT Number	NCT05710848
Lead Sponsor	SURGE Therapeutics
Conditions	Non-muscle-invasive Bladder Cancer
Enrollment	75 participants
Start Date	2023-07-11
Primary Completion	2026-05 (estimated)
Study Completion	2026-08 (estimated)
Updated on ClinicalTrials.gov	2026-05-27